Nogapendekin alfa inbakicept-pmln plus BCG now covers high-grade papillary-only disease, based on extrapolation from CIS efficacy data.
News|Articles|October 15, 2026
Anktiva for Papillary NMIBC: What Nurses Need to Know About the Regimen
Author(s)Alex Biese
Fact checked by: By ONN Staff
A Moffitt nurse practitioner explains rollout, handling, triage, and patient education for nogapendekin alfa inbakicept-pmln plus BCG.
Advertisement
Advertisement
The US Food and Drug Administration's (FDA) October 14, 2026, expansion of nogapendekin alfa inbakicept-pmln (Anktiva) with Bacillus Calmette-Guérin (BCG) to adults with BCG-unresponsive, high-grade non-muscle invasive bladder cancer (NMIBC) with papillary-only tumors brings a long, instillation-based regimen to a larger group of patients.
Related to this article
Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events.
FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.
An FDA advisory panel voted to approve GRAIL's Galleri multi-cancer early detection test for adults 50+. Read key oncology nursing takeaways.
FDA approves belzutifan with lenvatinib for advanced clear cell RCC after PD-1/PD-L1 inhibitor failure. Review LITESPARK-011 data and nursing takeaways.
Life table analysis estimates residual ovarian cancer risk by current age and planned age at risk-reducing surgery.
FDA-approved subcutaneous isatuximab via on-body injector changes myeloma care workflows. Experts outline what nurses and PAs need to know.
Advertisement
Advertisement